Post by UCL Business Ltd

NICE has today announced that AUCATZYL® can be made available on the NHS to eligible patients with acute lymphoblastic leukaemia! 🥳 This huge step forward means the pioneering immunotherapy treatment, developed by UCLB spinout venture Autolus Therapeutics, will be available to NHS patients ‘within weeks’. It can be used in adult patients with acute lymphoblastic leukaemia (ALL), which has not responded to treatment or has returned. AUCATZYL® is the product name for a variant of CAR T-cell therapy which reprogrammes a patient’s T-cells to recognise and target the specific signature of their cancer. These cells are then returned to the body as ‘living medicine’. Crucially, obe-cel is a major improvement on existing CAR T technology, which remains active in the body over longer periods and causes fewer side effects. The NICE - National Institute for Health and Care Excellence decision follows approval of AUCATZYL® by the UK Medicines and Healthcare products Regulatory Agency (MHRA) earlier this year. It has also been approved for use in eligible patients in the U.S and in the EU. Congratulations to Martin Pule, Chris Williams and the whole Autolus team on this important obe-cel milestone that will change people’s lives. Learn more about this approval and the innovative, life-saving treatment here: https://lnkd.in/eZ77MP6q